NasdaqGS:TXGLife Sciences
Is 10x Genomics (TXG) Fully Valued Following Its Lausanne Cancer Diagnostics Collaboration?
10x Genomics (TXG) stock is in focus after the company announced a multi year research collaboration with Lausanne University Hospital to study cancer diagnostics using its single cell and spatial platforms.
See our latest analysis for 10x Genomics.
The Lausanne collaboration lands at a moment when 10x Genomics has been in sharp focus, with the share price at US$47.27 and a 30 day share price return of 21.05% feeding into a 90 day share price return of 110.74% and a 1 year total shareholder...